Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07459790 Neovasculgen Cystitis, Interstitial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07459790 clinical trial report covering Neovasculgen, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07459751 Pimurutamab(Shanghai Henlius Biotech, Inc.) Squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07459751 clinical trial report covering Pimurutamab(Shanghai Henlius Biotech, Inc.), Phase 2/3, endpoints, sponsor, geography, readout timing and develo
Latest Hotspot
8 min read
ChiCTR2600120404 Butylphthalide Multiple System Atrophy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600120404 clinical trial report covering Butylphthalide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07463313 Cyclophosphamide Thymoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07463313 clinical trial report covering Cyclophosphamide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07469722 Hydrochlorothiazide Acute congestive heart failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07469722 clinical trial report covering Hydrochlorothiazide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07475065 Lumbricus rubellus extract Diabetic Neuropathies Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07475065 clinical trial report covering Lumbricus rubellus extract, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space
Latest Hotspot
8 min read
ChiCTR2600120745 CMS-D001 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600120745 clinical trial report covering CMS-D001, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07472491 Gadobutrol Central Nervous System Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07472491 clinical trial report covering Gadobutrol, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07476443 Ascorbic Acid Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07476443 clinical trial report covering Ascorbic Acid, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07480161 Umbilical Cord-Derived Mesenchymal Stem Cells(Ankara City Hospital Bilkent) Erectile dysfunction due to diabetes mellitus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07480161 clinical trial report covering Umbilical Cord-Derived Mesenchymal Stem Cells(Ankara City Hospital Bilkent), Phase 2/3, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07485595 JS1-1-01 Depressive Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07485595 clinical trial report covering JS1-1-01, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120959 Bevacizumab biosimilar(Jiangsu Hengrui Pharmaceuticals Co., Ltd.) Advanced Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600120959 clinical trial report covering Bevacizumab biosimilar(Jiangsu Hengrui Pharmaceuticals Co., Ltd.), Phase 2/3, endpoints, sponsor, geography